BMP2 and melanoma: Our RNAseq analysis revealed that a subset of melanoma cells from patients under MAPK-inhibition had a strong expression of BMP-2 when compared to therapy-naïve patients (median 0.48 vs 4.10 counts per million, P=0.06, t-test, Fig. 1B).